Anfotericina B Richet (Amphotericin B Deoxycholate) is an important therapeutic agent commonly used for managing severe, systemic fungal infections that present with noticeable physiological strain. Its application is relevant in clinical settings marked by increased discomfort and the need for timely support. This agent is relevant for conditions such as Aspergillosis, Cryptococcosis, Histoplasmosis, and Mucormycosis.

Main Therapeutic Focus

This medication is commonly used across conditions presenting with invasive systemic mycoses caused by a wide range of highly pathogenic fungi. The therapeutic support involves addressing the source of infection, which is relevant in contexts involving heightened systemic burden. For patients in these acute scenarios, it may provide support that helps ease the overall symptom burden and assists with symptomatic relief. It is applied in clinical settings that involve acute or unstable symptom patterns, often used when symptoms intensify and supportive relief is needed. This includes addressing symptom clusters that may become intense or disruptive, such as persistent, high-grade fevers and signs of organ or central nervous system involvement in critically ill, immunocompromised patient groups.

Quick Fact: Relief for Systemic Stress

This medication is commonly used to help manage the severe, widespread symptoms related to systemic imbalance, particularly in high-risk patients requiring immediate intervention.

Regulatory References

1. NIH review on Antifungal Agents

Who can and cannot use Anfotericina B Richet?

The eligibility profile for Amphotericin B Deoxycholate (the active ingredient) is strictly defined by regulatory documents based on patient history and disease characteristics. This medication is reserved for the treatment of progressive and potentially life-threatening systemic fungal infections.

Populations Excluded or Contraindicated

The medicine is contraindicated in patients with a known history of hypersensitivity to Amphotericin B or any of its components. Additionally, regulatory labeling states the medicine must NOT be used for noninvasive forms of fungal disease, such as oral thrush, in patients with normal neutrophil counts.

Conditional Use and Age-Related Rules

Use in patients with reduced renal function is classified as conditional use and requires close clinical observation and frequent monitoring of kidney function.

For pregnancy, use is conditional, permitted only if the treating physician determines the benefit outweighs the risk to the fetus. During lactation, a decision must be made to either discontinue nursing or discontinue the drug due to unknown excretion.

Pediatric patients are generally considered eligible, as use is not expected to cause different problems than in adults. However, there is no specific comparative data documented for use in the elderly population.

Interactions with Other Medicines and Products

Amphotericin B Deoxycholate (Anfotericina B Richet) has an officially documented interaction profile structured around specific pharmacodynamic reinforcement and administration constraints. The regulatory labeling does not classify any combinations as absolute contraindications, but interactions are noted to require caution due to enhanced toxicity or potentiated effects of the drug.

Interactions Affecting Organ Function

Co-administration with other nephrotoxic medications, such as aminoglycosides, cyclosporine, or pentamidine, may enhance the potential for drug-induced renal toxicity as documented in prescribing information. A similar effect on renal toxicity is noted with certain antineoplastic agents, including nitrogen mustard.

Interactions Related to Electrolyte Imbalance

Use with agents that potentiate potassium loss, such as corticosteroids, corticotropin (ACTH), and specific diuretics, may enhance Amphotericin B-induced hypokalemia (low potassium). This resulting hypokalemia may, in turn, potentiate the toxicity of digitalis glycosides and enhance the curariform effect of skeletal muscle relaxants.

Administration and Clearance Constraints

Regulatory information specifies constraints related to administration timing and clearance. The co-administration of Flucytosine may increase Flucytosine toxicity, potentially due to its impaired renal excretion and increased cellular uptake. Furthermore, acute pulmonary reactions have been reported when this medicine is administered during or shortly after leukocyte transfusions, necessitating the temporary separation of these infusions as far as possible.

Targeting the Fungal Cell Membrane

This mechanism centers on the molecule's high binding affinity for ergosterol, the primary sterol in the fungal cell membrane, which acts as the drug's key biological target. The binding leads to the rapid self-assembly of ion channels or pores that breach the cell's outer barrier, initiating a cascade of membrane permeabilization.

Cascade of Electrochemical and Oxidative Collapse

The formation of transmembrane pores results in the immediate, uncontrolled efflux of essential monovalent cations ( K^+) and protons ( H^+), causing the depolarization and catastrophic loss of the cell's electrochemical gradient. This primary fungicidal mechanism is supported by the drug's ability to induce Reactive Oxygen Species (ROS), which inflict secondary oxidative damage on the remaining intracellular components, contributing to the fungicidal outcome of the fungal organism.

️ Mechanism Selectivity and Immune Support

The drug's mechanism is defined by its differential binding selectivity between fungal ergosterol and mammalian cholesterol, where the varying affinity between the pathogen's sterol and host sterol establishes a constraint on its mechanistic action. Furthermore, the molecular action includes stimulating host phagocytic cells, which contributes to the systemic clearance of the destroyed fungal pathogens following the initial cell lysis.

How Anfotericina B Richet is Used: Administration Guidelines

Anfotericina B Richet, containing Amphotericin B Deoxycholate, is administered strictly via intravenous (IV) infusion only. Its use is limited to clinical settings under close medical observation, establishing it as a hospital-supervised therapy.

Dosing and Schedule

Administration begins with a mandatory initial test dose of 1 mg, which is infused over 20 to 30 minutes to gauge patient tolerance. Following the test, the initial daily dose is typically 0.25 mg/kg of body weight, administered once daily. The dose is then gradually increased daily until a maintenance range of 0.5 to 0.7 mg/kg is achieved, with the total daily dose not to exceed 1.5 mg/kg. If the treatment is interrupted for more than seven days, therapy must be restarted at the lowest initial dosage level.

Preparation and Procedural Rules

These instructions define a controlled, standardized protocol for the administration and preparation of the medicine.

Research Evidence / Overview of Studies for Anfotericina B Richet

Research for Anfotericina B Richet, which contains Amphotericin B Deoxycholate (ABD), has primarily focused on the clinical evaluation of severe invasive mycoses. The evidence base includes foundational studies and modern Randomized Controlled Trials (RCTs) where ABD often functions as a control or comparator against newer antifungal agents.

The research examined overall mortality and composite outcomes of Therapeutic Success, which includes measurements of patient survival and fungal clearance. Studies report how clinical status evolved in critically ill and immunocompromised patients, which make up the primary population studied.

ABD was also evaluated for use as empiric treatment—when a fungal infection is strongly suspected but not confirmed, particularly in febrile, neutropenic patients. Trials in this setting monitored outcomes related to changes in symptom activity, such as the pattern of fever, and a composite endpoint that includes measurements of survival.

While this formulation has a long history, evidence is limited in certain areas. Follow-up durations were often limited to the acute treatment phase, meaning long-term effects are not fully established. Comparative evidence is lacking against every current standard treatment, and results apply only to the specific populations studied, meaning subgroup findings remain uncertain.

Key Studies & References Amphotericin B - StatPearls - NCBI Bookshelf

Common questions about Anfotericina B Richet (FAQ)

Q: What should be monitored, and how often, when taking this medication?

According to official regulatory information, frequent monitoring of renal (kidney) function is recommended during treatment. Official product information notes that following the initial test dose, it is standard practice to monitor and record the patient's temperature, pulse, respiration, and blood pressure every 30 minutes for a period of 2 to 4 hours.

Q: What is the typical duration of treatment for systemic fungal infections?

Official product information indicates that the total dosage and duration required to eliminate specific systemic fungal infections are not fully defined in all cases. Prolonged therapy is typically necessary for effective treatment, and for some conditions, such as aspergillosis, treatment has been reported to last up to nearly a year.

Q: What should I do if I miss a scheduled dose?

Regulatory documents address the interruption of therapy. If the infusion is stopped for a period longer than seven days, the official guidance states that the protocol requires restarting treatment at the lowest initial dosage level before gradually increasing the amount again.

Storage and Disposal of Anfotericina B Richet

Official regulatory guidelines define strict conditions for storing Anfotericina B Richet (Amphotericin B Deoxycholate) to ensure its integrity.

Storage Requirements

The unopened vial must be kept in the refrigerator, protected from light. The reconstituted solution is stable for up to 7 days when refrigerated, but the final intravenous infusion solution must be used immediately after preparation. The product must not be frozen at any stage.

Disposal and Safety

All expired or unused medicine, including partially used vials, must be discarded according to official regulatory guidelines. The medication must be kept out of the sight and reach of children.